Evidence map›Paper›PMID 42368556›Full record

ArticleActa pharmaceutica Sinica. B2026

Discovery and mutasynthetic optimization of ansatrienin B: A new broad-spectrum inhibitor against RNA viruses.

Xu Zheng, Hongji Li, Mengxue Zhang, Zhiyue Qiu, Xingchi Yang, Ziwei Zhou, Wei Wu, Dunning Yu, Xiaofan Zhu, Zhiyong Chu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xu ZhengSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Hongji LiSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Mengxue ZhangSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhiyue QiuState Key Laboratory of Bioorganic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China.
Xingchi YangSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Ziwei ZhouState Key Laboratory of Bioorganic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China.
Wei WuSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Dunning YuSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Xiaofan ZhuSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhiyong ChuSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Haoran PengSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Cuiling DingSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Ping ZhaoSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Wen LiuUniversity of Chinese Academy of Sciences, Beijing 100049, China.
Wanchao YinState Key Laboratory of Bioorganic and Natural Products Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Shanghai 200032, China.
Yangang LiuSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Peng SunSchool of Pharmacy, Department of Microbiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RNA viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), flaviviruses, and alphaviruses, represent a major source of emerging human infectious diseases. They pose a persistent threat to public health; however, few therapeutic options are available for severe infections. Through a natural product screening campaign, we identified ansatrienin B as a broad-spectrum inhibitor of multiple RNA viruses, including SARS-CoV-2, flaviviruses (

Indexed as

AnsatrieninBroad-spectrum antiviralMutasynthesisNatural productRdRpRNA virusSARS-CoV-2West Nile virus

Identifiers

PMID42368556
PMCPMC13304725

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.